Kyverna Therapeutics, Inc. Common Stock (KYTX)
$4.42 -$0.07 (-1.57%) 10:50 PM 12/14/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$190.82M -
Day's Range
$4.25 - $4.58 -
Volume
431,550 -
52 Week Low / High
$3.92 - $35.06 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
- 3
- Strong Buy
- 2
- Buy
- 1
- Hold
- 0
- Sell
- 0
- Strong Sell
- $34.75
- Target Price
Company News
-
JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc — Oct 10th, 2024
Overview of the Recent Transaction On September 30, 2024, JPMorgan Chase & Co. made a significant addition to its investment portfolio by acquiring 2,380,021 shares of Kyverna Therapeutics Inc (NASDAQ:KYTX), a clinical-stage biopharmaceutical company. This transaction, executed at a price...
-
JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc — Oct 10th, 2024
Overview of the Recent Transaction On September 30, 2024, JPMorgan Chase & Co. made a significant addition to its investment portfolio by acquiring 2,380,021 shares of Kyverna Therapeutics Inc (NASDAQ:KYTX), a clinical-stage biopharmaceutical company. This transaction, executed at a price...
-
JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc — Oct 10th, 2024
Overview of the Recent Transaction On September 30, 2024, JPMorgan Chase & Co. made a significant addition to its investment portfolio by acquiring 2,380,021 shares of Kyverna Therapeutics Inc (NASDAQ:KYTX), a clinical-stage biopharmaceutical company. This transaction, executed at a price...
-
JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc — Oct 10th, 2024
Overview of the Recent Transaction On September 30, 2024, JPMorgan Chase & Co. made a significant addition to its investment portfolio by acquiring 2,380,021 shares of Kyverna Therapeutics Inc (NASDAQ:KYTX), a clinical-stage biopharmaceutical company. This transaction, executed at a price...
-
JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc — Oct 10th, 2024
Overview of the Recent Transaction On September 30, 2024, JPMorgan Chase & Co. made a significant addition to its investment portfolio by acquiring 2,380,021 shares of Kyverna Therapeutics Inc (NASDAQ:KYTX), a clinical-stage biopharmaceutical company. This transaction, executed at a price...
-
JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc — Oct 10th, 2024
Overview of the Recent Transaction On September 30, 2024, JPMorgan Chase & Co. made a significant addition to its investment portfolio by acquiring 2,380,021 shares of Kyverna Therapeutics Inc (NASDAQ:KYTX), a clinical-stage biopharmaceutical company. This transaction, executed at a price...
-
JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc — Oct 10th, 2024
Overview of the Recent Transaction On September 30, 2024, JPMorgan Chase & Co. made a significant addition to its investment portfolio by acquiring 2,380,021 shares of Kyverna Therapeutics Inc (NASDAQ:KYTX), a clinical-stage biopharmaceutical company. This transaction, executed at a price...
-
JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc — Oct 10th, 2024
Overview of the Recent Transaction On September 30, 2024, JPMorgan Chase & Co. made a significant addition to its investment portfolio by acquiring 2,380,021 shares of Kyverna Therapeutics Inc (NASDAQ:KYTX), a clinical-stage biopharmaceutical company. This transaction, executed at a price...
Similar Stocks
Portfolio
Comprised of 1 portfolios